Vitamin C for prevention of acute kidney injury in high-risk critically ill patients: a pilot randomized controlled trial study

Professor Rinaldo Bellomo0 个研究点目标入组 50 人开始时间: 2019年6月28日最近更新: 2021年7月21日

适应症

试验速览

暂无简介。

•Within first 24 hours of intensive care unit admission
•NephroCheck urine test positive result which is defined as a value exceeding more than 2 ng per ml / 1000.
•No evidence of acute kidney dysfunction on intensive care unit admission defined as a serum creatinine measured being less than 150 mircomol/L
•No chronic kidney disease defined by the stage II or greater using the Kidney Disease Improving Global Outcomes classification
•Are expected to stay in the ICU at least until the day after tomorrow.
•Use of indwelling urinary catheter as standard care expected for at least 72 hours after enrolment
•At least one of the following acute conditions within 24 hours prior to enrolment, which define clinical high-risk of AKI
•Respiratory Sequential Organ Failure Assessment (SOFA) score of equal to or greater than 2 (PaO2/FiO2 < 300)
•Cardiovascular SOFA score of equal to or greater than 1 (Mean arterial pressure less than 70 mmHg and/or any vasopressor required)

•DNR (do not resuscitate) DNI (do not intubate) orders
•Death is deemed imminent or inevitable during this admission, and either the attending physician, patient or substitute decision-maker is not committed to active treatment
•Already receiving dialysis (either acute or chronic) or imminent need of dialysis at the time of enrolment
•Known moderate to severe AKI prior to enrolment (KDIGO stage II or greater)
•Receiving kidney transplantation
•Any other illness that, in the investigator’s judgement, will substantially increase the risk associated with patient's participation in this study
•Patients with known HIV infection
•Patients with known or suspected history of oxalate nephropathy or hyperoxaluria, scurvy, chronic iron overload, G-6PD deficiency
•Clinician expects to prescribe high dose vitamin C for another indications
•Patients with known haemochromatosis.

发起方

Professor Rinaldo Bellomo